Business Context and Reporting Period
Vallon Pharmaceuticals, Inc. filed this Form 8-K on December 13, 2022, announcing a proposed merger with GRI Bio, Inc. GRI will survive as a wholly owned subsidiary of Vallon, subject to stockholder, regulatory, Nasdaq and other closing conditions. The filing does not provide operating results for GRI or Vallon for a reporting quarter or year.
Following closing, Marc Hertz, GRI’s current chief executive officer, is expected to become Vallon’s CEO. The post-closing board is expected to comprise four GRI-designated directors and one Vallon-designated director.
Key Financial and Transaction Metrics
| Item | Disclosure |
|---|---|
| Bridge financing | Up to approximately $3.3 million aggregate principal amount of senior secured notes, issued for up to approximately $2.5 million of cash proceeds in two approximately $1.67 million tranches. |
| First bridge closing | Scheduled for December 14, 2022, with approximately $1.25 million of cash proceeds. |
| Second bridge closing | Scheduled for the first business day after effectiveness of the Form S-4 registration statement, with approximately $1.25 million of cash proceeds. |
| Pre-Merger Financing | Approximately $12.25 million of cash investment, plus cancellation of outstanding bridge-note principal and interest immediately before the merger closing. |
| Vallon net cash assumption | The exchange-ratio range assumes Vallon net cash of between negative $3.5 million and negative $2.5 million. |
| Post-closing ownership | GRI equityholders are expected to own approximately 83.0% to 96.7% of Vallon; existing Vallon equityholders are expected to own approximately 17.0% to 3.3%, calculated on an adjusted fully diluted treasury-stock-method basis and before the Series A-1, A-2 and T Warrants. |
| Termination fees | Generally $2.0 million payable by the party terminating in specified circumstances; certain circumstances provide for expense reimbursement of up to $0.4 million. |
| Registration failure payments | If required resale registration statements are not timely filed or maintained, affected holders may receive 1.5% of the aggregate purchase price of registrable securities on the failure date and an additional 1.5% every 30 days, subject to exceptions. |
The filing does not provide revenue, net income, cash-flow, margin, debt-balance, cash-balance or liquidity metrics for either company beyond the transaction-related amounts described above.
Material Changes and Financing Terms
- The merger agreement was signed on December 13, 2022. GRI equityholders’ ownership percentage may be adjusted in their favor to support compliance with Nasdaq initial-listing requirements.
- Vallon intends to seek stockholder approval for a reverse stock split, issuance of more than 20% of its pre-closing shares to GRI stockholders, amendments to an equity incentive plan and related executive-compensation matters.
- GRI’s options, warrants and restricted-stock awards will be converted into comparable securities relating to Vallon common stock, with share counts and exercise prices adjusted using the exchange ratio.
- The bridge notes are secured by a lien on GRI’s assets. The bridge financing also includes warrants to purchase an aggregate of 1,252,490 GRI shares at an exercise price of $1.33 per share before merger conversion.
- The investor will receive Initial Shares equal to approximately 10.19% of the estimated parent fully diluted number, additional escrowed shares potentially issuable upon specified share-price resets, and substantial Series A-1, A-2 and T warrants.
- The equity warrants have initial exercise prices tied to the post-closing per-share price: 20% for Series T, 22% for Series A-1 and 24% for Series A-2. Several warrants include cashless-exercise and anti-dilution provisions.
- Investor ownership is subject to customary 4.99% or 9.99% beneficial-ownership limitations.
Outlook, Risks and Unusual Items
- The transaction is expected to close within seven months of the merger-agreement date, subject to permitted extensions and satisfaction or waiver of conditions. The filing does not provide a firm closing date.
- Closing depends on stockholder approvals, effectiveness of the Form S-4, Nasdaq listing and continued listing, accuracy of representations, covenant compliance and the absence of legal restraints.
- There is no assurance that the merger or financing will close, that Nasdaq listing requirements will be satisfied, or that the anticipated ownership percentages and financing proceeds will be realized.
- The proposed reverse stock split, extensive warrant package, escrowed additional shares and potential share-price resets could materially increase dilution for existing Vallon stockholders.
- GRI’s bridge notes are secured, and their principal and interest are expected to be cancelled immediately before the closing in connection with the equity financing.
- The filing identifies risks involving clinical-trial timing, regulatory approvals, product development and commercialization, intellectual property, competition, future financing needs, restructuring costs and the ability to maintain Nasdaq listing.
- Lock-up agreements generally restrict specified holders from transferring securities until the earliest of specified Rule 144 conditions, the first anniversary of the pre-merger financing or effectiveness of the resale registration statement, followed by an additional 90-day period as described in the filing.
Facts Investors Should Verify
- Whether the bridge tranches and approximately $12.25 million equity financing actually close, and the amount of bridge debt and interest cancelled.
- The final exchange ratio, reverse-stock-split ratio and resulting ownership percentages.
- The total number of shares and warrants issuable to the financing investor, including escrowed additional shares and reset-related issuances.
- Whether Vallon and the combined company satisfy Nasdaq listing and initial-listing requirements.
- Effectiveness of the Form S-4 and subsequent resale registration statement, including any registration-failure payment obligations.
- Stockholder approvals, merger closing conditions, termination rights and any applicable termination fees.
- The combined company’s actual cash balance, debt, operating expenses, clinical-development plans and need for additional financing, none of which is quantified clearly in this 8-K.